These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 19644228)

  • 1. High doses of rotigotine transdermal patch: results of an open-label, dose-escalation trial in patients with advanced-stage, idiopathic Parkinson disease.
    Rektor I; Babic T; Boothmann B; Polivka J; Boroojerdi B; Randerath O
    Clin Neuropharmacol; 2009; 32(4):193-8. PubMed ID: 19644228
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rotigotine transdermal patch enables rapid titration to effective doses in advanced-stage idiopathic Parkinson disease: subanalysis of a parallel group, open-label, dose-escalation study.
    Babic T; Boothmann B; Polivka J; Rektor I; Boroojerdi B; Häck HJ; Randerath O
    Clin Neuropharmacol; 2006; 29(4):238-42. PubMed ID: 16855426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term safety and efficacy of rotigotine transdermal patch for moderate-to-severe idiopathic restless legs syndrome: a 5-year open-label extension study.
    Oertel W; Trenkwalder C; Beneš H; Ferini-Strambi L; Högl B; Poewe W; Stiasny-Kolster K; Fichtner A; Schollmayer E; Kohnen R; García-Borreguero D;
    Lancet Neurol; 2011 Aug; 10(8):710-20. PubMed ID: 21705273
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overnight switch from oral dopaminergic agonists to transdermal rotigotine patch in subjects with Parkinson disease.
    LeWitt PA; Boroojerdi B; MacMahon D; Patton J; Jankovic J
    Clin Neuropharmacol; 2007; 30(5):256-65. PubMed ID: 17909303
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease.
    Watts RL; Jankovic J; Waters C; Rajput A; Boroojerdi B; Rao J
    Neurology; 2007 Jan; 68(4):272-6. PubMed ID: 17202432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term safety and tolerability of rotigotine transdermal system in patients with early-stage idiopathic Parkinson's disease: a prospective, open-label extension study.
    Elmer LW; Surmann E; Boroojerdi B; Jankovic J
    Parkinsonism Relat Disord; 2012 Jun; 18(5):488-93. PubMed ID: 22326237
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rotigotine transdermal system as add-on to oral dopamine agonist in advanced Parkinson's disease: an open-label study.
    Kim JM; Chung SJ; Kim JW; Jeon BS; Singh P; Thierfelder S; Ikeda J; Bauer L;
    BMC Neurol; 2015 Feb; 15():17. PubMed ID: 25879416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized study of rotigotine dose response on 'off' time in advanced Parkinson's disease.
    Nicholas AP; Borgohain R; Chaná P; Surmann E; Thompson EL; Bauer L; Whitesides J; Elmer LW;
    J Parkinsons Dis; 2014; 4(3):361-73. PubMed ID: 24643203
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rotigotine transdermal patch in combination therapy for Parkinson's disease--observations in routine clinical practice.
    Ceballos-Baumann A; Häck HJ
    Curr Med Res Opin; 2011 Oct; 27(10):1899-905. PubMed ID: 21867400
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of rotigotine transdermal patch for the treatment of apathy and motor symptoms in Parkinson's disease.
    Hauser RA; Slawek J; Barone P; Dohin E; Surmann E; Asgharnejad M; Bauer L
    BMC Neurol; 2016 Jun; 16():90. PubMed ID: 27267880
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rotigotine transdermal patch for the treatment of Parkinson's disease and restless legs syndrome.
    Boroojerdi B; Wolff HM; Braun M; Scheller DK
    Drugs Today (Barc); 2010 Jul; 46(7):483-505. PubMed ID: 20683503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rotigotine transdermal system for long-term treatment of patients with advanced Parkinson's disease: results of two open-label extension studies, CLEOPATRA-PD and PREFER.
    LeWitt PA; Boroojerdi B; Surmann E; Poewe W; ;
    J Neural Transm (Vienna); 2013 Jul; 120(7):1069-81. PubMed ID: 23208198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rotigotine: transdermal dopamine agonist treatment of Parkinson's disease and restless legs syndrome.
    Splinter MY
    Ann Pharmacother; 2007 Feb; 41(2):285-95. PubMed ID: 17213296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Continuous transdermal dopaminergic stimulation in advanced Parkinson's disease.
    Metman LV; Gillespie M; Farmer C; Bibbiani F; Konitsiotis S; Morris M; Shill H; Bara-Jimenez W; Mouradian MM; Chase TN
    Clin Neuropharmacol; 2001; 24(3):163-9. PubMed ID: 11391128
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rotigotine Transdermal Patch Does Not Make Parkinson Disease Patients Sleepy During Daytime.
    Ohta K; Osada T
    Clin Neuropharmacol; 2015; 38(6):231-5. PubMed ID: 26536020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. One year open-label safety and efficacy trial with rotigotine transdermal patch in moderate to severe idiopathic restless legs syndrome.
    Oertel WH; Benes H; Garcia-Borreguero D; Geisler P; Högl B; Trenkwalder C; Tacken I; Schollmayer E; Kohnen R; Stiasny-Kolster K;
    Sleep Med; 2008 Dec; 9(8):865-73. PubMed ID: 18753003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of long-term treatment with rotigotine transdermal system on dyskinesia in patients with early-stage Parkinson's disease.
    Giladi N; Ghys L; Surmann E; Boroojerdi B; Jankovic J
    Parkinsonism Relat Disord; 2014 Dec; 20(12):1345-51. PubMed ID: 25444083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial.
    Poewe WH; Rascol O; Quinn N; Tolosa E; Oertel WH; Martignoni E; Rupp M; Boroojerdi B;
    Lancet Neurol; 2007 Jun; 6(6):513-20. PubMed ID: 17509486
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transdermal rotigotine: double-blind, placebo-controlled trial in Parkinson disease.
    Jankovic J; Watts RL; Martin W; Boroojerdi B
    Arch Neurol; 2007 May; 64(5):676-82. PubMed ID: 17502466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High compliance with rotigotine transdermal patch in the treatment of idiopathic Parkinson's disease.
    Schnitzler A; Leffers KW; Häck HJ
    Parkinsonism Relat Disord; 2010 Sep; 16(8):513-6. PubMed ID: 20605106
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.